CN114042068A - Medicine prepared from neferine, capsaicin and 6-gingerol for inhibiting benign prostatic hyperplasia and application thereof - Google Patents
Medicine prepared from neferine, capsaicin and 6-gingerol for inhibiting benign prostatic hyperplasia and application thereof Download PDFInfo
- Publication number
- CN114042068A CN114042068A CN202111470728.7A CN202111470728A CN114042068A CN 114042068 A CN114042068 A CN 114042068A CN 202111470728 A CN202111470728 A CN 202111470728A CN 114042068 A CN114042068 A CN 114042068A
- Authority
- CN
- China
- Prior art keywords
- neferine
- gingerol
- capsaicin
- prostatic hyperplasia
- benign prostatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 title claims abstract description 113
- MIBATSHDJRIUJK-ROJLCIKYSA-N Neferine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-ROJLCIKYSA-N 0.000 title claims abstract description 79
- MIBATSHDJRIUJK-UHFFFAOYSA-N Neferine Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-UHFFFAOYSA-N 0.000 title claims abstract description 75
- 239000003814 drug Substances 0.000 title claims abstract description 69
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 title claims abstract description 60
- 229960002504 capsaicin Drugs 0.000 title claims abstract description 55
- 235000017663 capsaicin Nutrition 0.000 title claims abstract description 55
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 48
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 46
- 229940079593 drug Drugs 0.000 title claims abstract description 44
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 28
- 210000004027 cell Anatomy 0.000 claims abstract description 33
- 210000000064 prostate epithelial cell Anatomy 0.000 claims abstract description 10
- 230000001028 anti-proliverative effect Effects 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 210000001095 prostate stromal cell Anatomy 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 6
- 230000001603 reducing effect Effects 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract description 3
- 241000234314 Zingiber Species 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 description 27
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N testosterone group Chemical group [C@@H]12CC[C@H](O)[C@@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 26
- 210000002307 prostate Anatomy 0.000 description 21
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 11
- 102100038358 Prostate-specific antigen Human genes 0.000 description 11
- 229960003604 testosterone Drugs 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 229960004039 finasteride Drugs 0.000 description 7
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 210000005267 prostate cell Anatomy 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229960001712 testosterone propionate Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 235000002780 gingerol Nutrition 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- XBGUIVFBMBVUEG-UHFFFAOYSA-N 1-methyl-4-(1,5-dimethyl-4-hexenylidene)-1-cyclohexene Chemical compound CC(C)=CCCC(C)=C1CCC(C)=CC1 XBGUIVFBMBVUEG-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- AJPXZTKPPINUKN-UHFFFAOYSA-N Isoliensinin Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-UHFFFAOYSA-N 0.000 description 1
- AJPXZTKPPINUKN-FIRIVFDPSA-N Isoliensinine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-FIRIVFDPSA-N 0.000 description 1
- XCUCMLUTCAKSOZ-FIRIVFDPSA-N Liensinine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-FIRIVFDPSA-N 0.000 description 1
- XCUCMLUTCAKSOZ-JSOSNVBQSA-N Liensinine Natural products C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-JSOSNVBQSA-N 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 208000021891 Micturition disease Diseases 0.000 description 1
- 241000209445 Nelumbonaceae Species 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- YHBUQBJHSRGZNF-HNNXBMFYSA-N alpha-bisabolene Natural products CC(C)=CCC=C(C)[C@@H]1CCC(C)=CC1 YHBUQBJHSRGZNF-HNNXBMFYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229930003493 bisabolene Natural products 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of biological medicines, and particularly relates to a benign prostatic hyperplasia inhibiting medicine prepared from neferine, capsaicin and 6-gingerol and application thereof. The medicine for inhibiting benign prostatic hyperplasia comprises one or more of capsaicin, neferine and 6-gingerol. The capsaicin can inhibit the growth of prostate epithelial cells, various cancer cells have an anti-proliferation effect, the neferine can be used as 5 alpha-reductase for inhibiting and further resisting prostatic hyperplasia/hypertrophy, and the 6-gingerol is one of active ingredients extracted from ginger and has the pharmacological effects of resisting oxidation, reducing blood fat, diminishing inflammation and resisting proliferation.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a benign prostatic hyperplasia inhibiting medicine prepared from neferine, capsaicin and 6-gingerol and application thereof.
Background
Benign prostatic hyperplasia is a common urinary tract disorder in men and is characterized by hyperplasia of the prostate gland and smooth muscle. Resulting in urethral compression of patients, urinary retention and urethral infection. The disease is better for middle-aged men over 50 years old, and the incidence rate of the disease is increased year by year with the increase of the elderly population. Causing benign prostatic hyperplasia is associated with an androgen imbalance, which causes prostatic hyperplasia through androgen receptors and interfering signaling pathways.
Clinically, surgery and medicine are adopted to treat symptoms caused by prostatic hyperplasia. The aim of drug therapy is to specifically relax prostate smooth muscle and reduce prostate volume. Alpha receptor blockers cause contraction of prostate smooth muscle by blocking sympathetic nerve excitation, reducing micturition disorders, but are prone to hypotensive side effects. Blocking the conversion of androgens to dihydroandrogens by 5 alpha reductase inhibitors reduces prostate volume hyperplasia.
In modern pharmacological research, the traditional Chinese medicine prescription medicine for prostate mainly utilizes active ingredients of medicinal materials. The traditional Chinese medicine composition inhibits the hyperplasia of prostate cells through interfering a signal path. However, there are fewer studies in this area and fewer therapeutic drugs are being developed. Therefore, the invention provides a new treatment scheme for reducing the side effect of the existing oral medicines for treating the benign prostatic hyperplasia and reducing the urination disorder caused by the benign prostatic hyperplasia. Especially aims at improving symptoms such as androgen level imbalance and the like existing in a patient with chronic prostatic hyperplasia, thereby improving the life quality of the patient.
Disclosure of Invention
In order to solve the technical problems, the invention provides a benign prostatic hyperplasia inhibiting medicine prepared from neferine, capsaicin and 6-gingerol and application thereof.
The invention aims to provide a benign prostatic hyperplasia inhibiting medicine prepared from capsaicin, neferine and 6-gingerol, wherein the benign prostatic hyperplasia inhibiting medicine comprises one or more of the combination of the capsaicin, the neferine and the 6-gingerol.
Preferably, in the above drugs, when the benign prostatic hyperplasia treatment drug is a combination of capsaicin and neferine and acts on cells, the molar ratio of the capsaicin to the neferine is 1: 1-10; preferably, the molar ratio of the capsaicin to the neferine is 1: 10;
when the benign prostatic hyperplasia treatment drug is a combination of capsaicin and neferine and acts on animals, the mass ratio of the capsaicin to the neferine is 5: 1.
When the benign prostatic hyperplasia treatment drug is a combination of 6-gingerol and neferine and acts on cells, the molar ratio of 6-gingerol to neferine is 1: 1-10; preferably, the molar ratio of the 6-gingerol to the neferine is 1: 10;
when the benign prostatic hyperplasia treatment drug is a combination of 6-gingerol and neferine and acts on animals, the mass ratio of 6-gingerol to neferine is 5: 1.
The invention also provides the application of capsaicin, neferine and 6-gingerol in preparing the benign prostatic hyperplasia inhibiting medicine.
Preferably, in the above uses, the medicament for inhibiting benign prostatic hyperplasia is used for preparing the inhibitor for human prostatic epithelial cells and human normal prostatic stromal cells.
Preferably, in the above application, the benign prostatic hyperplasia inhibiting drug is prepared into a pharmaceutically acceptable dosage form, and the dosage form is tablets, granules, powder, oral liquid or capsules.
Preferably, in the above use, the concentration of each of capsaicin, neferine and 6-gingerol in the drug for inhibiting benign prostatic hyperplasia is 10 to 100 μ M.
Preferably, in the above use, when capsaicin and neferine are combined, the concentrations of capsaicin and neferine are 10 μ M and 100 μ M, respectively, or 10 μ M and 10 μ M, respectively.
Preferably, in the above application, when the 6-gingerol and the neferine are combined, the concentrations of the 6-gingerol and the neferine are respectively 10 μ M and 100 μ M, or respectively 10 μ M and 10 μ M.
Preferably, in the above use, the benign prostatic hyperplasia-inhibiting drug is used for preparing an anti-proliferative drug for benign prostate in a male human or a male mammal.
Preferably, in the above use, the male mammal is a mouse, and the amounts of capsaicin, neferine and 6-gingerol used in the mouse are 10mg/kg, 2mg/kg and 10mg/kg, respectively.
Compared with the prior art, the invention has the following beneficial effects:
the invention treats prostate diseases by inhibiting prostate hyperplasia, resisting inflammation and improving local microcirculation. The capsaicin is one of the active ingredients of the capsicum, and has the pharmacological effects of relieving pain, relieving itching, resisting oxidation, resisting cancer, resisting hyperplasia, resisting inflammation, resisting lipid peroxidation, and the like; the research of the invention shows that the capsaicin with the concentration of 100 mu M can inhibit the growth of prostate epithelial cells by 46 percent at 48, and the capsaicin also has the anti-hyperplasia effect on various cancer cells.
The plumula Nelumbinis is green embryo of mature seed of Nelumbo nucifera Gaertn of Nymphaeaceae, and its extract contains liensinine, isoliensinine, neferine, nuciferine, hyperin, rutin, etc. The neferine is one of active ingredients extracted from green plumula Nelumbinis of mature seed of Nelumbo nucifera Gaertn of Nelumbonaceae, and has antiarrhythmic, blood pressure lowering, platelet aggregation inhibiting, antioxidant, anti-inflammatory, and antiproliferative physiological effects; the research of the invention shows that neferine can be used as 5 alpha-reductase for inhibiting, and further resisting prostatic hyperplasia/hypertrophy.
The rhizoma Zingiberis recens extract is fresh rhizome extract of rhizoma Zingiberis recens of Zingiber of Zingiberaceae, and contains gingerol, shogaol, bisabolene, gingerol, etc. The 6-gingerol is one of active ingredients extracted from rhizoma Zingiberis recens, and has antioxidant, blood lipid reducing, antiinflammatory, and antiproliferative physiological effects.
In the invention, neferine, capsaicin and 6-gingerol are used as 5 alpha-reductase inhibitors and as drugs for inhibiting cell proliferation, and the neferine, the capsaicin and the 6-gingerol can be used as drugs, health-care food or food additives for relieving symptoms of prostatic hyperplasia/hypertrophy.
Drawings
FIG. 1 shows the expression of 5. alpha. -reductase, PSA protein, in human prostate epithelial cells of the present invention, after 24 hours of exposure to various concentrations of compounds.
Detailed Description
In order that those skilled in the art will better understand the technical solutions of the present invention to be implemented, the present invention will be further described with reference to the following specific embodiments and accompanying drawings.
Experimental example 1 anti-prostate cell proliferation
The purpose of this experimental example is to verify that capsaicin 10. mu.M and 100. mu.M, neferine 10. mu.M and 100. mu.M, and 6-gingerol 10. mu.M and 100. mu.M have the effect of resisting prostate cell proliferation by cell experiments. All drugs were dissolved in dimethyl sulfoxide solution, which was less than 0.1%, v/v, and added to the medium. Culturing human prostate epithelial cell strain LNCaP and human normal prostate stromal cell WPMY-1 in 96-well plate with appropriate cell culture solution at 37 deg.C with 5% CO2Incubating for about 48h under the condition, and adding the medicine after the cells are attached and grow on the culture disc. LNCaP cells were incubated in RPMI-1640 medium and WPMY-1 cells were incubated in DMEM medium.
Drug addition experiments were divided into 9 groups: (1) a control group, containing only culture medium and corresponding cells, without any drug addition; (2) capsaicin, which is calculated by the volume of a culture medium, and is respectively provided with two final concentration drug experiments of 10 mu M and 100 mu M; (3) the neferine group is respectively provided with two final concentration drug experiments of 10 mu M and 100 mu M based on the volume of the culture medium; (4) 6-gingerol group, which is calculated by the volume of the culture medium, and is respectively provided with two final concentration drug experiments of 10 mu M and 100 mu M; (5) the final concentrations of the high-concentration neferine and the capsaicin combined group are respectively set to be 100 mu M and 10 mu M based on the volume of the culture medium; (6) the final concentrations of the low-concentration neferine and capsaicin combined group are respectively set to be 10 mu M and 10 mu M in terms of the volume of the culture medium; (7) the high-concentration neferine is combined with the 6-gingerol group, and the final concentrations of the high-concentration neferine and the 6-gingerol group are respectively set to be 100 mu M and 10 mu M in terms of the volume of the culture medium; (8) the low-concentration neferine is combined with the 6-gingerol group, and the final concentrations of the two groups are respectively set to be 10 mu M and 10 mu M according to the volume of the culture medium; (9) the positive control group finasteride (Shanghai Aladdin Biotechnology Co., Ltd.) was prepared by 10. mu.M and 100. mu.M of the culture medium by volume. When the drug is added, the drug is prepared into stock solution with the concentration more than 1000 times of the final concentration, then the addition amount of the stock solution is calculated according to the final concentration, and the stock solution is added into the culture medium, so that the phenomenon of killing cells by a solvent is avoided.
After 48h incubation, washed with PBS (pH7.4, potassium dihydrogen phosphate 2mM, disodium hydrogen phosphate 8mM, sodium chloride 136mM, potassium chloride 2.6mM) and replaced with fresh medium, 10. mu. LMTT (5mg/ml) was added to each well, and 5% CO was added at 37 ℃ to the wells2After incubation for 4h in a cell incubator, the liquid in the wells was removed and 100. mu.L of dimethyl sulfoxide was added to dissolve the purple crystals. And uniformly mixing the liquid in each hole, taking out the sample, placing the sample at room temperature for 20min, measuring the absorbance at 570nm, and calculating the cell activity.
Cell activity ═ (absorbance of experimental group-absorbance of control group)/(absorbance of control group) × 100%.
The results of the cell activity calculation are shown in table 1, the experimental data in table 1 are expressed by mean ± standard deviation, the statistical analysis of the experimental results is performed, and the difference with P <0.05 is statistically significant. The results in Table 1 demonstrate that capsaicin, neferine, 6-gingerol and combinations thereof all have significant antiproliferative effects on prostate epithelial cell glandular stromal cells.
TABLE 1 measurement of cell Activity
Note: denotes P <0.05 compared to control group.
Experimental example 2 antiandrogen-induced prostate cell proliferation
The purpose of this experimental example is to verify that capsaicin 10. mu.M and 100. mu.M, neferine 10. mu.M and 100. mu.M, and 6-gingerol 10. mu.M and 100. mu.M have the effect of resisting prostate cell proliferation by cell experiments. All the medicines are dissolved by dimethyl sulfoxide solution and then added into a culture medium,the concentration of the dimethyl sulfoxide solution is less than 0.1 percent, v/v. Culturing human prostate epithelial cell strain LNCaP and human normal prostate stromal cell WPMY-1 in 96-well plate with appropriate cell culture solution at 37 deg.C with 5% CO2Incubating for about 48h under the condition, and adding the medicine after the cells are attached and grow on the culture disc. LNCaP cells were incubated in RPMI-1640 medium and WPMY-1 cells were incubated in DMEM medium. When the drug is added, the drug is prepared into stock solution with the concentration more than 1000 times of the final concentration, then the addition amount of the stock solution is calculated according to the final concentration, and the stock solution is added into the culture medium, so that the phenomenon of killing cells by a solvent is avoided.
Drug addition experiments were divided into 14 groups: (1) a control group, containing only culture medium and corresponding cells, without any drug addition; (2) testosterone group, the final concentration of the drug is set to be 1 mu M based on the volume of the culture medium; (3) the final concentration of the drug is respectively set to be 1 mu M and 10 mu M by the volume of the culture medium in the testosterone combined low-concentration capsaicin group; (4) the final concentration of the drug is respectively 1 mu M and 100 mu M based on the volume of the culture medium by combining testosterone with high-concentration capsaicin; (5) the final concentrations of the testosterone group and the low-concentration neferine group are respectively set to be 1 mu M and 10 mu M based on the volume of the culture medium; (6) the final concentrations of the testosterone group and the high-concentration neferine group are respectively set to be 1 mu M and 100 mu M based on the volume of the culture medium; (7) testosterone is combined with a low-concentration 6-gingerol group, and the final concentrations of the drugs are respectively set to be 1 mu M and 10 mu M based on the volume of a culture medium; (8) the final concentration of the drug is respectively set to be 1 mu M and 100 mu M by the volume of the culture medium by combining the testosterone with the high-concentration 6-gingerol group; (9) the final concentrations of the combination of testosterone and high-concentration neferine and capsaicin are respectively set to be 1 mu M, 100 mu M and 10 mu M based on the volume of a culture medium; (10) the final concentrations of the drug in the testosterone group combined with the low-concentration neferine and the capsaicin group are respectively set to be 1 mu M, 10 mu M and 10 mu M based on the volume of the culture medium; (11) testosterone is combined with high-concentration neferine and 6-gingerol, and the final concentrations of the medicaments are respectively set to be 1 mu M, 100 mu M and 10 mu M in terms of the volume of a culture medium; (12) the final concentrations of the testosterone, the low-concentration neferine and the 6-gingerol group are respectively set to be 1 mu M, 10 mu M and 10 mu M according to the volume of a culture medium; (13) positive control group: the combination of testosterone and low-concentration finasteride (Shanghai Aladdin Biotechnology Co., Ltd.) comprises 1 μ M and 10 μ M of the medicine respectively based on the volume of the culture medium; (14) positive control group: the combination of testosterone and finasteride (Shanghai Aladdin Biotechnology Co., Ltd.) with high concentration is set to 1 μ M and 100 μ M respectively based on the volume of the culture medium. When the drug is added, the drug is prepared into a stock solution with a concentration more than 1000 times of the final concentration, and then the stock solution is added into the culture medium, so that the phenomenon of killing cells by a solvent is avoided.
After 48h incubation, washed with PBS (pH7.4, potassium dihydrogen phosphate 2mM, disodium hydrogen phosphate 8mM, sodium chloride 136mM, potassium chloride 2.6mM) and replaced with fresh medium, 10. mu. LMTT (5mg/ml) was added to each well, and 5% CO was added at 37 ℃ to the wells2After incubation for 4h in a cell incubator, the liquid in the wells was removed and 100. mu.L of dimethyl sulfoxide was added to dissolve the purple crystals. And uniformly mixing the liquid in each hole, taking out the sample, placing the sample at room temperature for 20min, measuring the absorbance at 570nm, and calculating the cell activity.
Cell activity ═ (absorbance of experimental group-absorbance of control group)/(absorbance of control group) × 100%.
The results of the cell activity calculations are shown in table 2, where the experimental data in table 2 are expressed as mean ± standard deviation, and the experimental results are statistically analyzed, and the difference with P <0.05 is statistically significant. The results in Table 2 demonstrate that capsaicin, neferine, 6-gingerol and combinations thereof all have significant antiproliferative effects on prostate epithelial cell glandular stromal cells.
TABLE 2 measurement of cell Activity
Note: denotes P <0.05 compared to control group. # denotes P <0.05 compared to testosterone.
Experimental example 3 anti-androgen induces expression of 5 alpha-reductase and PSA protein in prostate epithelial cells
In benign prostatic hyperplasia, testosterone is converted into dihydrotestosterone by 5 alpha-reductase, and if the expression of the 5 alpha-reductase is effectively reduced, prostatic cell hyperplasia can be inhibited. Capsaicin (10 mu M and 100 mu M), neferine (10 mu M and 100 mu M), 6-gingerol (10 mu M and 100 mu M) and neferine (100 mu M) are respectively combined with 6-gingerol (100 mu M) and capsaicin (100 mu M) to act on LNCaP cells according to the experimental method of example 1, cell proteins are extracted after 24 hours, the expression levels of 5 alpha-reductase and PSA protein in the cells are detected, and the effect of the compound on inhibiting the androgen-induced prostate cell proliferation by regulating the expression of the two proteins is evaluated.
FIG. 1 is a graph showing the protein level expression of 5. alpha. -reductase and PSA proteins in prostate epithelial cells after they have been exposed to different concentrations of the compound for 24 hours. Beta-actin is an internal reference. The results in FIG. 1 show that neferine (10, 100. mu.M), 6-gingerol (10, 100. mu.M), and capsaicin (10, 100. mu.M) have the effect of inhibiting prostate 5. alpha. -reductase, thereby reducing PSA expression, exhibiting an antiproliferative effect.
Example 4 animal experiments with benign prostatic hyperplasia
Animal and reagent preparation: in this example, 42 healthy male mice were purchased, aged about 6 to 7 weeks and weighed between 20 to 30g, and were kept for 1 week after purchase. The environment for raising male mice was set at 23 + -1 deg.C and 12h/12h day and night cycle, and these male mice were able to eat and drink water by themselves.
On the other hand, a finasteride reagent (Shanghai Aladdin Biotechnology Co., Ltd.) was prepared at a concentration of 10mg/kg, and a corn oil was used as a solvent for the preparation of the finasteride reagent. Corn oil is purchased from Xian Yuelai pharmaceutical science and technology Limited as a pharmaceutical adjuvant.
Grouping: the mice were randomly divided into 7 groups of 6 mice each, (1) vehicle group with 0.2mL corn oil as additive; (2) a model group, namely a model mouse constructed by the following method; (3) a capsaicin group, wherein the added medicine is 10mg/kg of capsaicin; (4) the neferine group is added with 2mg/kg neferine; (5) 6-gingerol group, the added medicine is 10mg/kg 6-gingerol; (6) compounding, wherein the added medicines comprise capsaicin 10mg/kg and neferine 2 mg/kg; or the combination of 2mg/kg of neferine and 10mg/kg of 6-gingerol; (7) in the positive control group, the added medicament is finasteride 10 mg/kg.
Note that "mg/kg" in the above group means the amount added per kg body weight of the mouse.
Experimental experiments: a mouse was obtained by intramuscular-injecting a testosterone propionate solution (Shanghai Alatin Biotechnology Co., Ltd.) at a concentration of 7.5mg/kg once a day, 150. mu.L of the testosterone propionate solution each time, and orally administering the resulting solution for two weeks using a feeder to thereby cause benign prostatic hyperplasia. After sacrifice, blood samples were taken from the heart. Before analyzing the sample, blood was centrifuged at 3000g for 10min after coagulation to obtain serum, which was stored at-20 ℃. Prostate specific antigen content in serum was determined using the prostate specific antigen kit (jingmei ELSIA kit). The mice take the prostate and clear the adjacent blood vessels and connective tissue. The sham operated control group was also removed from its prostate via the same manner as described above. The prostate index is calculated as the weight of the total weight of the prostate gland over the total body weight: prostate index (total prostate weight/total body weight) x 100%, results are shown in tables 3-4. From the data in tables 3 and 4, it is known that testosterone propionate promotes a significant increase in prostate wet weight, prostate index and PSA, which is evidence of prostate hyperplasia. The results show that the neferine, the 6-gingerol and the capsaicin have the effect of resisting prostatic hyperplasia by using the neferine (2mg/kg), the 6-gingerol (10mg/kg) and the capsaicin (10mg/kg) singly or in combination to effectively reduce and promote the wet weight of prostate, the prostate index and the PSA.
TABLE 3 Effect of neferine, 6-gingerol, capsaicin alone and in combination on mouse serum PSA
Group of | PSA(ng/mL) |
Vector set | 1978.10±293.705# |
Model group: testosterone propionate 7.5mg/kg | 2642.42±107.14* |
Neferine 2mg/kg | 2332.88±38.01*# |
Capsaicin 10mg/kg | 2412.22±119.77*# |
6-gingerol 10mg/kg | 2318.27±268.58*# |
2mg/kg of neferine and 10mg/kg of 6-gingerol | 2059±123.66# |
Neferine 2mg/kg + Capsici fructus 10mg/kg | 1983.5±53.51# |
Finasteride 10mg/kg | 2342.99±219.98*# |
Note: denotes P <0.05 compared to vehicle group and # denotes P <0.05 compared to model group.
TABLE 4 influence of neferine, 6-gingerol, capsaicin alone and in combination on prostate wet weight in mice
Note: denotes P <0.05 compared to vehicle group and # denotes P <0.05 compared to testosterone propionate group.
It should be noted that, when the present invention relates to a numerical range, it should be understood that two endpoints of each numerical range and any value between the two endpoints can be selected, and since the steps and methods adopted are the same as those in the embodiment, in order to prevent redundancy, the present invention describes a preferred embodiment. While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (10)
1. The medicine for inhibiting benign prostatic hyperplasia is prepared from capsaicin, neferine and 6-gingerol, and is characterized in that the medicine for inhibiting benign prostatic hyperplasia contains one or more of the combination of capsaicin, neferine and 6-gingerol.
2. The drug for inhibiting benign prostatic hyperplasia, which is prepared from capsaicin, neferine and 6-gingerol according to claim 1, wherein when the drug for treating benign prostatic hyperplasia is a combination of capsaicin and neferine and acts on cells, the molar ratio of the capsaicin to the neferine is 1: 1-10;
when the benign prostatic hyperplasia treatment drug is a combination of capsaicin and neferine and acts on an animal, the mass ratio of the capsaicin to the neferine is 5: 1;
when the benign prostatic hyperplasia treatment drug is a combination of 6-gingerol and neferine and acts on cells, the molar ratio of 6-gingerol to neferine is 1: 1-10;
when the benign prostatic hyperplasia treatment drug is a combination of 6-gingerol and neferine and acts on animals, the mass ratio of 6-gingerol to neferine is 5: 1.
3. Use of capsaicin, neferine, and 6-gingerol for the preparation of the medicament according to claim 1 for inhibiting benign prostatic hyperplasia.
4. Use according to claim 3, wherein the medicament for inhibiting benign prostatic hyperplasia is used for preparing an inhibitor of human prostate epithelial cells and human normal prostate stromal cells.
5. The use according to claim 1, wherein the benign prostatic hyperplasia inhibiting drug is formulated into a pharmaceutically acceptable dosage form, which is a tablet, granule, powder, oral liquid or capsule.
6. The use as claimed in claim 5, wherein the concentrations of capsaicin, neferine and 6-gingerol in the medicament for inhibiting benign prostatic hyperplasia are 10-100 μ M.
7. The use as claimed in claim 6, wherein the concentrations of capsaicin and neferine are 10 μ M and 100 μ M, respectively, or 10 μ M and 10 μ M, respectively, when the capsaicin and neferine are combined.
8. The use according to claim 6, wherein when 6-gingerol and neferine are combined, the concentrations of 6-gingerol and neferine are 10 μ M and 100 μ M, respectively, or 10 μ M and 10 μ M, respectively.
9. The use according to claim 5, wherein the benign prostatic hyperplasia-inhibiting medicament is used for preparing a benign prostatic anti-proliferative medicament for male humans or male mammals.
10. The use according to claim 9, wherein the male mammal is a mouse, and the amounts of capsaicin, neferine, and 6-gingerol used in the mouse are 10mg/kg, 2mg/kg, and 10mg/kg of body weight, respectively.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111470728.7A CN114042068A (en) | 2021-12-03 | 2021-12-03 | Medicine prepared from neferine, capsaicin and 6-gingerol for inhibiting benign prostatic hyperplasia and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111470728.7A CN114042068A (en) | 2021-12-03 | 2021-12-03 | Medicine prepared from neferine, capsaicin and 6-gingerol for inhibiting benign prostatic hyperplasia and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114042068A true CN114042068A (en) | 2022-02-15 |
Family
ID=80212426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111470728.7A Pending CN114042068A (en) | 2021-12-03 | 2021-12-03 | Medicine prepared from neferine, capsaicin and 6-gingerol for inhibiting benign prostatic hyperplasia and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114042068A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001288077A (en) * | 2000-04-07 | 2001-10-16 | Shokun An | Therapeutic agent for chronic prostatitis, prostatomegaly, hemorrhoids and erection failure utilizing capsaicin |
CN101862374A (en) * | 2010-06-12 | 2010-10-20 | 李宏 | Lotus plumule and new application of extractive thereof |
CN101862331A (en) * | 2009-04-14 | 2010-10-20 | 中国中医科学院中药研究所 | New use of methyl liensinine |
CN101862312A (en) * | 2009-04-14 | 2010-10-20 | 中国中医科学院中药研究所 | New application of 6-gingerol |
CN104856995A (en) * | 2015-04-24 | 2015-08-26 | 西安交通大学 | Application of lotus plumule active alkaloid in preparation of prostate drugs |
CN113546065A (en) * | 2021-09-07 | 2021-10-26 | 宜春学院 | Application of 6-gingerol in preparing medicine for treating and preventing prostate cancer and resisting prostate cancer metastasis |
-
2021
- 2021-12-03 CN CN202111470728.7A patent/CN114042068A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001288077A (en) * | 2000-04-07 | 2001-10-16 | Shokun An | Therapeutic agent for chronic prostatitis, prostatomegaly, hemorrhoids and erection failure utilizing capsaicin |
CN101862331A (en) * | 2009-04-14 | 2010-10-20 | 中国中医科学院中药研究所 | New use of methyl liensinine |
CN101862312A (en) * | 2009-04-14 | 2010-10-20 | 中国中医科学院中药研究所 | New application of 6-gingerol |
CN101862374A (en) * | 2010-06-12 | 2010-10-20 | 李宏 | Lotus plumule and new application of extractive thereof |
CN104856995A (en) * | 2015-04-24 | 2015-08-26 | 西安交通大学 | Application of lotus plumule active alkaloid in preparation of prostate drugs |
CN113546065A (en) * | 2021-09-07 | 2021-10-26 | 宜春学院 | Application of 6-gingerol in preparing medicine for treating and preventing prostate cancer and resisting prostate cancer metastasis |
Non-Patent Citations (1)
Title |
---|
杨小青等: "甲基莲心碱和异莲心碱对5α-还原酶抑制作用的研究", 《中国药师》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hu et al. | Melatonin inhibits endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in lipopolysaccharide-induced endometritis in mice | |
Yakubu et al. | Antidiarrhoeal activity of aqueous extract of Mangifera indica L. leaves in female albino rats | |
AU2009252911C1 (en) | Composition comprising 1, 3 /1, 6 beta glucan for reducing weight | |
May et al. | The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial | |
Yan et al. | Aqueous extracts of Herba Cistanche promoted intestinal motility in loperamide‐induced constipation rats by ameliorating the interstitial cells of cajal | |
BR112016010509B1 (en) | USES OF A SOLID ORAL DOSAGE FORM | |
TWI776234B (en) | Pharmaceutical compositions and uses thereof in treating muscle atrophy | |
CN111265599A (en) | Application of lycopene and grape seed composition in preparation of medicine for treating arthritis | |
CN101474271B (en) | Medicament for treating uarthritis | |
Raghavendran et al. | Ginsenoside rich fraction of Panax ginseng CA Meyer improve feeding behavior following radiation-induced pica in rats | |
CN114042068A (en) | Medicine prepared from neferine, capsaicin and 6-gingerol for inhibiting benign prostatic hyperplasia and application thereof | |
KR20180117065A (en) | Composition for preventing, improving or treating stress diseases comprising Platycodi Radix extract | |
CN110613712B (en) | Chinese medicinal composition and its application in treating vasculitis and endothelial injury | |
CN104922277B (en) | Schisandra chinens P.E is in the application for preparing rescue paraquat poisoning drug | |
CN111956751A (en) | Pharmaceutical composition for treating hyperuricemia and preparation method thereof | |
US7556828B2 (en) | Pharmaceutical composition for treatment of BPH and preparation thereof | |
Odukanmi et al. | Kolaviron modulates intestinal motility and secretion in experimentally altered gut functions of Wistar rats | |
US20040101584A1 (en) | Control of cancer with annonaceous extracts | |
Xu et al. | Polydatin alleviates hyperuricemia combined with gouty arthritis in mice via regulating urate transporters, NLRP3 inflammasome and NF-κB pathway | |
Tope et al. | Mechanisms of antiulcerogenic effect of garlic (Allium sativum) in albino rats | |
JP4706174B2 (en) | α-Glucosidase inhibitor | |
Lumlerdkij | Thai traditional medicine as a source for cancer prevention: from local concepts to the discovery of potential chemopreventive extracts | |
JP4779316B2 (en) | Monoamine reuptake inhibitor with dicoppi | |
Rahman et al. | Antidepressant-like effect of methanolic extract of Punica granatum (pomegranate) in mice model of depression | |
KR100773246B1 (en) | Composition comprising of trillium kamtschaticum extracts as an effective ingredient for decreasing weight gain and lowering plasma glucose level |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |